



## AGENDA WUOF 2016 - BUENOS AIRES

### WUOF CONFERENCE 2016 - Innovation in Urologic Oncology

Thursday October 20, 2016

Hilton Buenos Aires

#### Conference Co-Chairs

Laurence Klotz, MD

Nathan Lawrentschuk, MD

Marcelo Bendhack, MD

#### WELCOME & INTRODUCTIONS

Chairman's Welcome & Framing of Theme | Laurence Klotz, MD | Canada  
(talks to be 12 minutes + 3 minute discussion unless otherwise indicated)

8:00

SESSION ONE | KIDNEY CANCER | Co-moderators: Peter Hammerer & Aaron Torres Garcia

- Biopsy should be done routinely for most small renal masses | Antonio Finelli MD | Canada
- Biopsy should not be done routinely for most small renal masses | Fernando Secin, MD | Argentina
- Most SRMs should be managed with ablation rather than surgery | Peter Black, MD | Canada
- SRMs needing treatment should be managed with surgical resection | Mark Frydenberg MD | Australia

#### DISCUSSION

9:00

SESSION TWO | LOCALIZED PROSTATE CANCER | Moderator: Nathan Lawrentschuk

- Prostate biomarkers are ready for prime-time in routine detection of prostate cancer  
| Scott Eggener MD | USA
- The utility of prostate biomarkers for routine clinical practice has not been established  
| Badry Konety, MD | USA

#### DISCUSSION

- Prostate Cancer prevention is dead  
Pro: | E. David Crawford MD | USA  
Con: | Neil Fleshner MD | Canada

#### DISCUSSION



## AGENDA WUOF 2016 - BUENOS AIRES

10:00

SESSION THREE | Moderator: Ofer Yossepowich

- MRI can replace prostate biopsy in men with elevated PSA  
Pro: | Peter Pinto MD| USA  
Con: | Boris Hadaschik MD| Germany
- Predictors of prostate cancer specific mortality after radical prostatectomy | Damien Bolton MD| USA
- Pelvic LND with RP: Role of fluorescence mapping/PSMA CT PET | Karim Touijer MD| USA
- New Strategies to Target the Androgen Receptor | Christopher Evans MD| USA

DISCUSSION

11:15

SESSION FOUR | Moderator: Marcelo Bendhack

- The new Gleason grade scoring system: implications for decision making |Makarand Khochikar MD| India
- Why salvage is preferable to adjuvant radiation for men with positive margins  
| Nathan Lawrentschuk MD| Australia
- Radical prostatectomy in elderly patients | Derya Tilki MD| Germany
- Cardio-vascular complications of ADT | Jehonathan Pinthus MD| Canada

DISCUSSION

12:15 - 12:45

BREAK / LUNCH SERVICE

12:45

SESSION FIVE | Moderator: Laurence Klotz

### MAJOR OBSERVATIONS

Objectives: Three Key Opinion Leaders will identify the single most major observation in their field within the last 3 years. Each presenter will have 8 minutes to describe their observation, followed by 3 minutes of discussion

- Observation #1: Bladder | Seth Lerner MD| USA
- Observation #2: Testis | Arnulf Stenzl MD| Germany
- Observation #3: Prostate | Manish Patel MD | Australia



## AGENDA WUOF 2016 - BUENOS AIRES

13:20

SESSION SIX | PROSTATE CANCER | Moderator: Shrawan Singh

- Focal therapy is the treatment of choice for intermediate risk patients with a solitary clinically significant lesion on MRI  
PRO: | Judd W. Moul MD | USA  
CON: | Rob Reiter MD | USA
- Chemotherapy should precede AR targeted agents for hormone naïve metastatic disease in young patients | Fred Saad MD | Canada
- AR targeted agents should be used prior to chemo for hormone naïve metastatic disease  
| Axel Heidenreich MD | Germany
- Indications for Radium 223 in chemo-naïve patients | TBD MD |

DISCUSSION

14:20

SESSION SEVEN | UROTHELIAL CANCER | Moderator: Maurizio Brausi

- Controversies in the management of urethral cancer | Reynaldo Gomez MD | Chile
- Unmet needs in upper tract TCC | Shahrokh Shariat MD | Austria
- Using pathway analysis and metabolic signature to predict survival in MIBC | Seth Lerner MD | USA
- T2 and T3a bladder cancer: neoadjuvant chemotherapy should be standard  
PRO: | Ashish Kamat MD | USA  
CON: | Arnulf Stenzl MD | Germany

DISCUSSION

15:20

SESSION EIGHT | CHALLENGING CASE OF ADVANCED PROSTATE CANCER | Moderator: Nathan Lawrentschuk

International Perspectives in the Clinical Management of Prostate Cancer

Five (5 minute) clinical case presentations justifying each approach followed by a 15-minute open discussion

CASE: 65 year old male, Gleason 9 prostate cancer, T1c, PSA 15, 2 bone mets

- A Role for RP | Axel Heidenreich MD | Germany
- Management in Mexico | Arturo Mendoza-Valdes MD | Mexico
- An Indian perspective | Makarand Khochikar MD | India
- A North American perspective | Neil Fleshner MD | Canada

DISCUSSION

16:00 Final Thoughts & Adjournment | Laurence Klotz, MD | Canada